← Research Library

Tier 1 · Peer-reviewed primarycohortmoderaten = 2253

Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population

Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, Passarino G, Kennedy BK, Wei M, Cohen P, Crimmins EM, Longo VD · 2014 · Cell Metabolism

DOI: 10.1016/j.cmet.2014.02.006View source ↗

Respondents aged 50–65 reporting high protein intake had a 75% increase in overall mortality and a 4-fold increase in cancer death risk during the following 18 years.

Summary

This Cell Metabolism paper combined a large NHANES-based human cohort (2,253 adults followed over 18 years) with mouse experiments to ask whether high protein intake — especially animal protein — drives cancer and mortality risk via IGF-1 and growth-hormone signalling. The headline finding is age-dependent. In adults aged 50–65, those reporting high protein intake (≥20 percent of calories from protein) had a 75 percent higher overall mortality and a fourfold higher cancer death risk over the next 18 years compared to low-protein eaters (under 10 percent of calories). The effect was largely abolished when the protein came from plant sources rather than animal sources. After age 65, the relationship reversed: high protein became protective for cancer and overall mortality — though high protein at any age was associated with a fivefold increase in diabetes mortality. Mouse experiments supported the mechanism: high-protein diets accelerated tumour growth and elevated IGF-1, while protein restriction did the opposite. The interpretation is that protein's relationship with longevity is not monotonic; it depends on age, on the protein source, and on what's being optimized for.

Talking it through with practitioners

The free Skool community is where we discuss what new evidence means for actual cycles.

Join the free community →

Tags

Not medical advice. This page summarizes primary research. It is not a substitute for consultation with a qualified clinician. See safety for exclusion criteria.